Many pharmaceutical companies have started to look at their processes through the lens of valued, external partners. While companies will continue to evaluate the effectiveness of their external partners, many are increasingly looking in the mirror to see at what kind of partner they are to work with.
The continuing rise of patient-centricity within the drug development industry is a crucial consideration for sponsors when designing their clinical development plans. With initiatives such as the FDAs Patient-Focused Drug Development Program, patient experience and voice within a clinical trial is becoming increasingly important.
Otsuka Pharmaceutical has been an industry leader in TB drug development for over 30 years. The company is currently focused on MDR (multidrug-resistant)-TB, which refers to a form of the disease that is resistant to at least the two main first-line drugs available on the market.
In a recent clinical trial, many of the sites lacked proper personnel, training, and equipment. Learn how the company overcame these challenges to make the trial a success.
According to Roslyn F. Schneider MD, MSc, Global Patient Affairs Lead at Pfizer, patients can often have a feeling of being powerless, and be left with the impression they are there to serve the drug development process, and not the other way around. “There are times when it seems we are asking patients for their opinions simply so we can paste them in a pre-defined place in an existing system,” she says. “That is not how a company should be treating one of its most critical stakeholders. As an industry we need to continue to find new ways to incorporate participant feedback in a way that is good for patients, their families, and caregivers. This will be beneficial for our companies and societies as a whole since all of these stakeholders are very closely aligned.”
TransPerfect, a leading provider of solutions for global development and commercialization of products to the life sciences industry, announced that Aptalis Pharma ("Aptalis") has implemented Trial Interactive as its global pharmacovigilance system master file (PSMF) solution.
inVentiv Health, Inc., offering best-in-class clinical, commercial, and consulting services to the healthcare industry, recently announced that it has taken an equity stake in Mytrus, Inc., a pioneer in “virtual clinical trials” and technologies such as electronic informed consent to improve trial efficiency.
Janssen Research & Development, LLC (Janssen R&D) today announced the establishment of a global cross-pharmaceutical Investigator Databank designed to improve efficiencies of industry-sponsored clinical trials.
Agile Therapeutics announced today that Dr. Marie Foegh, Chief Medical Officer and Vice President of Clinical Research and Development, will be presenting at CBI's Forum on Phase II-III Clinical Study Optimization. The event takes place September 20-21, 2012 in Chicago.
INC Research, LLC, a therapeutically focused clinical research organization (CRO) with a Trusted Process® for delivering reliable results, recently announced the opening of a facility in South Korea to manage the growing demand for world-class clinical development programs. Located in the heart of Seoul's business district, the Company's South Korean team is primarily focused on study start-up and clinical operations activities around key therapeutic areas.
Merge Healthcare Incorporated (Nasdaq:MRGE), a leading provider of clinical systems and innovations that seek to transform healthcare, today announced that Worldwide Clinical Trials, Inc. has selected Merge's eClinical OS™ solution to accelerate study startup, streamline electronic data capture (EDC), and maximize operational efficiency across its Phase I-IV studies
Merge Healthcare Incorporated (Nasdaq:MRGE), a leading provider of clinical systems and innovations that seek to transform healthcare, today announced the release of Merge eClinical OS, a new clinical trial operating solution that provides first-of-its-kind, end-to-end study support for trials of all sizes through one interface, one consistent experience, one platform.